Clinical trials: SARS CoV-2
Vaccine
Double-blind, Placebo-controlled, Randomized Study of the Tolerability, Safety and Immunogenicity of an Inactivated Whole Virion Concentrated Purified Vaccine (CoviVac) Against Covid-19 of Children at the Age of 12-17 Years Inclusive"
Randomized, double-blind, placebo controlled, multi-center clinical trials of the tolerability, safety and immunogenicity of the inactivated whole-virion concentrated purified vaccine against COVID-19, manufactured by FSBSI…
- Trial name
- NCT05715918
- Testing
- Vaccine for intramuscular injection
- Where
- 4 sites in Russia
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- Chumakov Federal Scientific Center for Research and Development of Immune-and-Biological Products
COVID-19, Households
ARMOR-Household: Characterizing Transmission of COVID-19 in Households of SARS-CoV-2 Index Cases
The goal of this project is to understand the household level transmission dynamics and factors that predict transmission of SARS-COV-2 between pediatric and adults in the household.
- Conditions
- COVID-19, Households, SARS CoV 2 Infection
- Trial name
- NCT05467917
- Where
- United States
- Volunteers
- 374 people, healthy volunteers welcome
- Sponsor
- Columbia University
SARS-CoV-2 Infection, Kidney Transplant Infection
SARS-COV-2 Infection in Kidney Transplant Recipients: a Brazilian Multicenter Study
COVID-19 is the pandemic disease caused by the SARS-CoV-2 coronavirus. It is a highly contagious viral disease, the condition of which main clinical symptoms are characterized by fever and respiratory symptoms.
- Trial name
- NCT04494776
- Where
- Brazil
- Volunteers
- 500 people
- Sponsor
- Helio Tedesco Silva Junior
COVID-19
Antihistamines, Amantadine and Evolution of COVID-19
The rates of symptomatic COVID19 infection, hospital admission among COVID19 cases and survival would be quantified in patiens chronically treated with antihistamines or amantadine, with the aim of determining the role of…
- Trial name
- NCT05504057
- Testing
- Antihistamine, Amantadine
- Where
- 2 sites in Spain
- Volunteers
- 140,660 people, healthy volunteers welcome
- Sponsor
- Consorci Sanitari de Terrassa
COVID-19, Long COVID
Effectiveness of Transcranial Direct Current in Patients With Persistent COVID-19 With Headaches and Chronic Pain.
This study aims to verify the efficacy/effectiveness of treatment with transcranial direct current stimulation (TDCS) in patients with Long Covid who experience headaches, migraines, and chronic pain, such as arthralgia and…
- Conditions
- COVID-19, Long COVID, Long Covid19, SARS CoV 2 Infection
- Trial name
- NCT05780450
- Testing
- Transcranial Direct Current Therapy (tDCS)
- Where
- 2 sites in Spain
- Volunteers
- 87 people
- Sponsor
- Fundación Universidad Católica de Valencia San Vicente Mártir
SARS-CoV-2 Infection
Understanding the Long-term Impact of COVID on Children and Families
This is a combined retrospective and prospective, longitudinal, observational meta-cohort of individuals age 0-25 years who will enter the cohort with and without SARS-CoV-2 infection at varying stages before and after infection.
- Trial name
- NCT05172011
- Where
- 65 sites in United States
- Volunteers
- 15,028 people, healthy volunteers welcome
- Sponsor
- NYU Langone Health
Immune Response to Covid 19 Vaccination
Comparative Study of Patterns of Immune Response to COVID 19 Vaccination
An effective vaccine stands as the most effective way for controlling the COVID 19 pandemic , yet, immunogenic vaccine efficacy needs to be extensively studied .
- Trial name
- NCT05408299
- Testing
- Covid vaccines (Moderna - Pfizer- Astra Zeneca- Johnson and Johnson - Sinopahrm)
- Where
- Egypt
- Volunteers
- 100 people
- Sponsor
- National Research Centre, Egypt
SARS-CoV-2 Infection, COVID-19
A Phase 3 Study to Evaluate the Safety, Tolerability, and Immunogenicity of Multiple Production Lots and Dose Levels of BNT162b2 RNA-Based COVID-19 Vaccines Against COVID-19 in Healthy Participants
This is a Phase 3, randomized, observer-blind study in healthy individuals. The primary study will evaluate the safety, tolerability, and immunogenicity of the SARS-CoV-2 RNA vaccine candidate (BNT162b2): As a 30-microgram dose…
- Trial name
- NCT04713553
- Testing
- BNT162b2, BNT162b2.B.1.351
- Where
- 17 sites in United States
- Volunteers
- 1,574 people, healthy volunteers welcome
- Sponsor
- BioNTech SE
COVID-19, SARS-CoV-2 Infection
A Study to Evaluate the Immunogenicity and Safety of A Recombinant Protein COVID-19 Vaccine as Booster Vaccines
This study is a phase Ⅱ clinical trial to evaluate the safety and immunogenicity of SCTV01E-2 in people of different ages who had been vaccinated with COVID-19 vaccines.
- Trial name
- NCT05933512
- Testing
- SCTV01E-2, SCTV01E
- Volunteers
- 600 people, healthy volunteers welcome
- Sponsor
- Sinocelltech Ltd.
COVID-19
Serological and PCR Testing for COVID-19
Richmond Research Institute (RRI) is applying existing and new COVID-19 PCR and antibody tests to help develop methodologies which provide fast and accurate results.
- Trial name
- NCT04404062
- Testing
- Membrane-based immunoassay kit, Quantitative antibody Tests, PCR Test
- Where
- United Kingdom
- Volunteers
- 2,500 people, healthy volunteers welcome
- Sponsor
- Richmond Research Institute
COVID-19
Trial to Evaluate Nitazoxanide for Treatment of Mild COVID-19 in Subjects Not at High Risk of Severe Illness
The purpose of this study is to determine whether nitazoxanide (NTZ) is safe and effective for treatment of mild COVID-19 illness. Adults and adolescent participants will be followed for approximately 28 days.
- Trial name
- NCT05157269
- Testing
- Nitazoxanide, Vitamin Super-B Complex
- Sponsor
- Romark Laboratories L.C.
General Surgery, Disease Outbreaks
Short-term Outcome of Covid-19 Surgical Patients: Case-series of a High-risk Area Community Hospital
The investigators retrospectively evaluated all the patients operated in a high-risk community hospital from the first Italian case of Covid-19 (February 21st) to the April 10th (in order to have at least a 30-days follow-up).
- Trial name
- NCT04430062
- Testing
- Surgical procedures performed under general anesthesia
- Where
- Italy
- Volunteers
- 14 people
- Sponsor
- Azienda Socio Sanitaria Territoriale di Lodi
COVID, Drug Effect
New Antiviral Drugs for Treatment of COVID-19
Background: In December 2019, SARS-CoV-2 was isolated on Vero E6 and Huh7 cell lines after an outbreak of pneumonia of unknown origin in Wuhan, Hubei Province, China.
- Trial name
- NCT04392427
- Testing
- Treatment group: will receive a combination of Nitazoxanide, Ribavirin and Ivermectin for a duration of seven days :
- Where
- Egypt
- Volunteers
- 100 people
- Sponsor
- Mansoura University
COVID-19 Respiratory Infection
Insight Into the UAE Experience With Monoclonal Antibodies (Sotrovimab )
Sotrovimab is a newly developed monoclonal antibody for the treatment of mild and moderate COVID-19 patient, who are at high risk for progression to severe COVID-19, including hospitalization or death.
- Trial name
- EHS-Strategy (NCT05144178)
- Where
- United Arab Emirates
- Volunteers
- 3,500 people
- Sponsor
- Emirates Health Services (EHS)
COVID-19
Neonatal SARS-CoV-2 Anti-spike Protein Receptor-binding Domain Antibodies at Delivery
To assess the association between neonatal SARS-CoV-2 antibody level at delivery and infant COVID-19 infection under age 6 months, and to identify predictive factors for neonatal antibody level at delivery.
- Trial name
- NCT05564884
- Testing
- no intervantion
- Where
- Israel
- Volunteers
- 58 people
- Sponsor
- Rabin Medical Center
COVID-19
Effectiveness of Remedesvir in COVID-19 Patients Presenting at Mayo Hospital Lahore
Currently, several drugs including Remdesivir, hydroxychloroquine, chloroquine, ritonavir+lopinavir, Tocilizumab, Arbidol and interferon are under randomised controlled trials (RCTs) for efficacy and/or safety evaluations in…
- Trial name
- NCT04871633
- Testing
- Remdesivir, Conventional
- Where
- Pakistan
- Volunteers
- 66 people
- Sponsor
- King Edward Medical University
COVID
Post Covid-19 Cardiopulmonary and Immunological Changes
Study rationale and aim: Resolving the COVID-19 pandemic quickly hinges on a crucial factor: how well a person's immune system remembers SARS-CoV-2, the virus behind the disease, after an infection has resolved and the patient is…
- Trial name
- covid-19 (NCT04388436)
- Where
- Egypt
- Volunteers
- 100 people
- Sponsor
- Mansoura University
SARS-COV-2 Infections, COVID-19
Fight COVID-19 Trial
A 6-Week Prospective, Open label, Randomized, in Multicenter Study of, Oseltamivir 300mg per day plus Hydroxychloroquine 800 mg per day versus Combination of Lopipinavir 800mg (or 10 mg/kg ) per day and Ritonavir 200 mg ( or 2.5…
- Trial name
- FIGHT-COVID-19 (NCT04303299)
- Testing
- Oral
- Where
- Thailand
- Volunteers
- 320 people
- Sponsor
- Department of Medical Services Ministry of Public Health of Thailand
COVID-19
Clinical Performance Evaluation of the CareSuperb™ COVID-19 Antigen Home Test
The purpose of this study is to evaluate the accuracy of the CareSuperb™ COVID-19 Antigen Home Test (sensitivity and specificity) in a simulated home use environment when compared to the Roche cobas SARS-CoV-2 (EUA200009)…
- Trial name
- NCT05771714
- Testing
- CareSuperb COVID-19 Antigen Home Test Kit
- Where
- United States
- Volunteers
- 786 people, healthy volunteers welcome
- Sponsor
- AccessBio, Inc.
X-linked Agammaglobulinemia, XLA
COVID-19 Vaccine Responses in PIDD Subjects
The goal of our study is to assess the cellular immune responses of participants with antibody deficiency disease before and after immunization with SARS-CoV-2 mRNA vaccines.
- Conditions
- X-linked Agammaglobulinemia, XLA, Primary Immune Deficiency, CVID
- Trial name
- NCT05321407
- Where
- 3 sites in United States
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Duke University